CVVT - Centre for Virology, Vaccinology and Therapeutics 病毒與疫苗研究中心

25/08/2026

🥼「親歷病人苦況，成就更好的醫生」

顯微鏡外的生命啟示：袁國勇教授行醫半世紀，細說同理心與生死感悟

醫者的真正意義何在？行醫逾半世紀，香港大學微生物學系傳染病學講座教授兼 CVVT 總監袁國勇教授，一直站在科研與臨床的最前線。然而在早前的香港書展對談中，他真摯分享道：醫學中最深刻的領悟，往往不在顯微鏡下，而在於人與人之間的溫度。🫀

🔬在與著名精神科醫生苗延琼的深度對話中，袁教授回顧了其自傳《顯微鏡下看穹蒼：袁國勇自述》的心路歷程，放下科學家的光環，坦誠剖析生命的脆弱與無常：

● 苦難中的同理心： 幼年病痛與前線歷練，如何讓他深切體會患者與家屬之苦，成為醫者最珍貴的養分。👥
● 直面生命的短暫： 為何他鼓勵大家「每年寫一次遺願」，以此時刻提醒自己珍惜光陰、活在當下。⌛
● 未來醫療的羅盤： 面對科技變革與人口老化，新一代醫療領袖不可或缺的人文關懷與領導修養。🌟

灼見名家專訪報導 🔗 https://bit.ly/4qCwhy7 (中文）
CVVT 全文分享 🔗 https://bit.ly/4gvNF2O (英文）
完整對談精華重溫 🎥 https://bit.ly/4hL4g54 (中文）

-------------

🥼“Experiencing your patient’s suffering makes you a better doctor.”

Beyond the Microscope: Prof. KY Yuen on Empathy, Mortality, and Half a Century in HKU Medicine

What does it truly mean to heal? For over 50 years, Professor Yuen Kwok-yung has stood at the front lines of scientific discovery and clinical practice. Yet, as he shared during an intimate dialogue at the Hong Kong Book Fair, the most transformative lessons in medicine are not found under a lens, but etched into the human heart. 🫀

Sharing the stage with renowned psychiatrist Dr. May Miao, Prof. Yuen - Chair Professor of Infectious Diseases at HKU and Managing Director of CVVT - reflected on the poignant journey chronicled in his autobiography, 'My Life in Medicine: A Hong Kong Journey' (“顯微鏡下看穹蒼：袁國勇自述”). 🔬

Moving beyond laboratory breakthroughs, Prof. Yuen candidly explores:

● The Power of Empathy: Why personal vulnerability and understanding patient hardship are indispensable to becoming a compassionate healer. 👥
● Life’s Fragility: Why drafting an annual will serves as a grounding practice to cherish every fleeting moment. ⌛
● Future Leadership: The essential human qualities needed to guide the next generation through an evolving healthcare landscape. 🌟

Read the full article by Master Insight 🔗 https://bit.ly/4qCwhy7 (Chinese)
Read our full article 🔗 https://bit.ly/4gvNF2O (English)
Watch the full discussion 🎥 https://bit.ly/4hL4g54 (Chinese)

#香港大學 #袁國勇 #顯微鏡下看穹蒼 #醫者仁心 #人文醫學 #灼見名家

21/08/2026

07/08/2026

🎉 愛滋病治療重大突破！無須終身服藥有望成真？

由 CVVT（病毒與疫苗研究中心） 副主任兼港大醫學院（HKUMed） 陳志偉教授 團隊，聯同 Yicura 醫克生物（前稱 Immuno Cure） 研發嘅愛滋病 DNA 疫苗 ICVAX®，喺「功能性治癒」研究上取得重大突破！項目更獲 TVB 專題報道 📺

💡 亮點快速看：

❌ 打破傳統：目標令愛滋病患者喺無須長期服用抗病毒藥物（cART）嘅情況下，仍能依靠自身免疫系統持續控制病毒！
✅ 第一期臨床測試成功：證實安全且能誘發極佳嘅 T 細胞免疫反應，成效顯著！
🚀 邁向第二期測試：Yicura 醫克生物 與 HKUMed 團隊正全力準備跨中心第二期臨床試驗，離實地應用又近一步！
💰 獲政府強烈支持：獲研資局（RGC）累計撥款超過 1.13 億港元 支持科研轉化！

作為本土科研機構，CVVT 會繼續同產學研夥伴緊密合作，將頂尖研究轉化為實際醫療方案，為全球健康帶來改變！🇭🇰💪

—----------

🎉 Major HIV Treatment Breakthrough! Could a Life Free of Daily Medication Become Reality?

A major leap forward in HIV "functional cure" research! ICVAX®, a novel therapeutic DNA vaccine co-developed by Prof. Zhiwei Chen (Deputy Director of CVVT and Director of the AIDS Institute at HKUMed) and biotechnology firm Yicura 醫克生物 (formerly known as Immuno Cure), has hit a crucial milestone—and was recently featured on TVB News! 📺

💡 Highlights at a Glance:

❌ A New Life: Aims to allow people living with HIV to sustain long-term viral control through their own immune system without needing daily antiretroviral drugs (cART).
✅ Successful Phase I Clinical Trial: Proven safe and highly effective at boosting functional HIV-specific T-cell immune responses.
🚀 Moving to Phase II: Yicura and the HKUMed team are actively preparing for multi-centre Phase II clinical trials to evaluate real-world efficacy!
💰 Strong Government Backing: Granted over HK$113.8M in cumulative funding by the Research Grants Council (RGC) to accelerate translational impact.

As a local R&D centre, CVVT remains dedicated to collaborating with biotechnology leaders like Yicura to transform pioneering academic research into real-world healthcare solutions that make a global impact. 🇭🇰💪

📺 Watch the full TVB coverage: (Chinese) https://bit.ly/4xldHwp (English) https://bit.ly/4qashok

02/04/2026

🎉【亞洲首個整合式類器官精準醫學中心 – PDOHub™ HK 正式成立】🧫

我們欣然宣佈，由比幹生物、InnoHK 病毒與疫苗研究中心 (CVVT)、華大智造及臨床腫瘤學合作夥伴鄺麗雲教授共同合作的 PDOHub™ HK 正式成立！這是亞洲首個整合式類器官精準醫學中心，標誌著精準醫學發展的重要里程碑。

🧬 為何重要？
類器官技術能高度模擬真實器官的結構與功能，為疾病建模、藥物測試及個人化治療提供革命性工具。結合近十年的頂尖科研成果、自動化系統及臨床專業知識，PDOHub 將加速科研成果由實驗室邁向臨床應用，直接惠及患者。

🔬 合作焦點：

✅腫瘤學： 為合資格癌症患者提供「腫瘤類器官藥物敏感性測試」，涵蓋食道癌、胃癌、大腸癌、三陰性乳癌及肺癌等。

✅傳染病： 結合專利類器官平台與自動化技術，增強香港對抗新發傳染病及應對疫情的能力。

我們將攜手推動轉化研究，為患者、臨床醫生及公共衛生決策提供更快速、精準的科學見解。

🔗 想了解更多的詳情，請瀏覽 👉https://bit.ly/4bNvuET

-------------

🎉Asia’s First Integrated Organoid-Based Precision Medicine Centre – PDOHub™ HK Launched 🧫

We are excited to announce the establishment of PDOHub™ HK, Asia’s first integrated Organoid-Based Precision Medicine Centre, through a strategic collaboration between BiomOrgan Limited (BiomOrgan), InnoHK Centre for Virology, Vaccinology, and Therapeutics (CVVT), MGI Tech Co., Ltd. (MGI), and clinical oncology partner Professor Dora Kwong from Queen Mary Hospital.

🧬 Why It Matters:
Organoids are advanced 3D cell cultures that mimic real human organs, enabling precise disease modelling, drug testing, and personalised treatment. Powered by nearly a decade of cutting-edge research from the team at The University of Hong Kong, automation, and clinical expertise, PDOHub aims to accelerate the journey from bench to bedside, bringing real benefits to patients.

🔬 Key Focus Areas:

✅Oncology: Providing Tumour Organoid Drug Sensitivity Tests for eligible cancer patients, including esophageal, stomach, colorectal, triple-negative breast, and lung cancers.

✅Infectious Diseases: Combining patented organoid platforms with automation to strengthen Hong Kong’s pandemic preparedness and response capabilities.

Together, we are driving translational research and delivering faster, actionable insights for patients, clinicians, and public health decision-making.

🔗 Read more about this monumental launch! 👉https://bit.ly/4sP7w21

#類器官 #精準醫學 #癌症研究 #傳染病 #轉化醫學 #香港創新

20/03/2026

🏆 CVVT 於日內瓦奪得驕人成績！🌍

超興奮宣佈 ！我們在第五十一屆日內瓦國際發明展勇奪 5 個獎項！

🇨🇭 來自 40 個國家的1,000＋ 項發明中，我們與 #香港大學 合作的的多項尖端生物科技創新脫穎而出：
🏅 1 項評審團嘉許金獎
🥇 3 項金獎
🥈 1 項銀獎
從牙刷式黏膜免疫、類器官模型、廣譜流感抗體、mRNA超級細菌疫苗，到迷你舌頭生物感測器——我們正全力革新傳染病防控！🔬💉
🔗 想了解更多得獎發明的詳情，請瀏覽 👉 http://bit.ly/3Nrdk2k

這項佳績充分證明我們研究團隊鍥而不捨的探索精神和解決難題的決心。👏

我們滿懷靈感，從日內瓦回到香港。現在正是時候將這份國際認同轉化為實際影響力，回到實驗室，繼續為革新傳染病防控工作而努力！🔬💉

-------------

🏆Golden Moment for CVVT in Geneva! 🌍

Thrilled to announce that CVVT has brought home 5 medals from the 51st International Exhibition of Inventions in Geneva!

🇨🇭 We showcased our cutting-edge biotech innovations amongst 1,000+ inventions from 40 countries, and our collaboration with The University of Hong Kong has earned us top honours:
🏅 1x Gold Medal with Congratulations of the Jury
🥇 3x Gold Medals
🥈 1x Silver Medal

From revolutionary mucosal immunity via toothbrushing to next-gen organoid models, broad-spectrum flu antibodies, mRNA vaccines against superbugs, and even a mini tongue biosensor — we're pushing the boundaries of infectious disease control! 🔬💉

🔗 Read more about each winning invention! 👉http://bit.ly/3Nrdk2k

This achievement is a testament to the relentless curiosity and problem-solving spirit of our research teams.👏

We returned to Hong Kong buzzing with inspiration. Now, it’s time to turn this global recognition into real-world impact. Back to the lab to continue revolutionising infectious disease control and prevention! 🔬💉

#生物科技 #生命科學 #日內瓦發明展 #創新 #轉化研究 #傳染病 #香港大學

11/03/2026

🌿【從實驗室到生活：濕疹護理的革命性突破！】🌿

2月12日，我們迎來了一個重大里程碑——由香港大學李嘉誠醫學院微生物學系團隊，經過超過十年深入研究，這項本土科研成果終於從實驗室走進現實生活！✨

由我們中心高一村教授及袁國勇教授帶領的團隊，成功破解濕疹反覆發作的關鍵機制：原來金黃色葡萄球菌過度繁殖，以及其釋放的毒素，才是引發炎症、痕癢及皮膚屏障受損的真正元兇！😮

傳統治療多數依賴類固醇或抗生素，但只能暫時紓緩症狀，更可能帶來皮膚萎縮和抗藥性風險。而這項突破的核心——植物複合配方安思靈®（Anesinin®）——不是單純殺菌，而是採用創新的「馴服」機制，精準抑制金黃色葡萄球菌的毒素，同時保留皮膚原有的微生物平衡，從源頭中和痕癢和炎症，為濕疹護理帶來全新選擇！🌱

-------------

🌿【From Lab to Life: A Revolutionary Breakthrough in Eczema Management!】🌿

On February 12, we celebrated a major milestone—after more than a decade of in-depth research by the Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, this homegrown scientific innovation has finally moved from the laboratory into real life! ✨

Led by Professor Richard Kao and Professor Kwok-yung Yuen, the team has successfully unraveled the key mechanism behind recurrent eczema flare-ups: the overgrowth of Staphylococcus aureus and the virulence factors (toxins) it releases are the real culprits triggering inflammation, itching, and skin barrier damage! 😮

Traditional treatments mostly rely on steroids or antibiotics, but these only temporarily suppress symptoms and may even lead to skin thinning and antibiotic resistance. At the heart of this breakthrough is Anesinin®, a plant-based complex formula that doesn't simply kill bacteria. Instead, it uses an innovative "taming" mechanism that precisely inhibits the toxins produced by Staphylococcus aureus while preserving the skin's natural microbial balance, tackling itching and inflammation at the source and offering a new option for eczema care! 🌱

26/02/2026

🧧Wishing everyone a happy, healthy, and prosperous Chinese New Year from the CVVT team! 🐴

As we welcome the Year of the Horse, we also celebrate our commitment to translating our scientific research into lasting health and well-being. Here’s to a year of forward momentum for science, for patients, and for all.

🌟祝大家新年快樂，身體健康🏮